"Antibody Responses to Haemophilus Influenzae Type B Vaccines in Men With" Human Immunodeficiency Virus Infection

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

"Antibody Responses to Haemophilus Influenzae Type B Vaccines in Men With" Human Immunodeficiency Virus Infection

New England Journal of Medicine (12/26/91) Vol. 325, No. 26, P. 1837
Steinhoff, Mark C. et al.

Abstract: Individuals with HIV infection that are immunized with the PRP-CRM conjugate vaccine early in the course of infection are inclined to protect against disease resulting from H. influenzae type b, write Mark C. Steinhoff et al. of The Johns Hopkins University in Baltimore, Md. Steinhoff et al. studied respones in 248 men who were randmomly assinged to receive a single dose of either the H. influenzae type b polysaccharide (PRP) or the polysaccharide-mutant diphtheria toxoid conjugate vaccine (PRP-CRM). The subjects were put into four different categories: seronegative men, men with asymptomatic HIV infection, men with symptomatic HIV infection, and men with AIDS. The subjects with AIDS had the lowest PRP-antibody titers before immunization. Subjects with asymptomatic HIV infection and those with symptomatic HIV infection showed a threefold greater increase in geometric mean antibody titers with PRP-CRM than with the PRP vaccine. Subjects with AIDS, however, had a greater antibody response to PRP vaccine.

911226
AD910002

Copyright © 1991 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.